Typical Vs Atypical Hemolytic Uremic Syndrome [best] Now

E. coli ) Genetic (complement dysregulation) Prodrome Bloody diarrhea (usually) None (usually), or upper respiratory infection Frequency ~90-95% of cases ~5-10% of cases (Rare) Recurrence Rare (usually one-time) Common (chronic/relapsing) Prognosis Good recovery with supportive care High risk of ESRD, dialysis, death Main Treatment Supportive (fluids, dialysis) Eculizumab (complement inhibitor) Detailed Breakdown Typical HUS (STEC-HUS) Epidemiology: Primarily affects children under 10, often after consuming contaminated food. Mechanism: Shiga toxins enter the bloodstream, bind to endothelial cells, and cause thrombosis (clotting) in small vessels. Outcome: Most children recover well with supportive treatment. ashpublications.org +2 Atypical HUS (aHUS) Epidemiology: Can affect all ages, often familial or sporadic. Mechanism: Uncontrolled alternative complement pathway activation leads to system-wide endothelial damage, particularly in the kidneys, but can affect the brain and heart. Management: Requires rapid initiation of complement inhibition therapy (e.g., eculizumab) to prevent irreversible organ damage. Complications: High rates of chronic kidney disease (CKD) and end-stage renal disease (ESRD). National Institutes of Health (.gov) +4 When to Suspect aHUS Atypical HUS should be suspected if a patient has TMA symptoms (anemia, low platelets, kidney damage) but tests negative for Shiga toxin and possesses normal ADAMTS13 activity (to rule out TTP). ScienceDirect.com +1 Note: Some experts argue for abandoning "atypical HUS" in favor of more specific terms like "complement-mediated TMA," as it better reflects the underlying mechanism. ScienceDirect.com This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes.

Atypical HUS, in contrast, is a rare but devastating disease that can affect individuals of any age, from infancy to adulthood. Its name, "atypical," belies its clinical gravity. Unlike typical HUS, aHUS is not preceded by STEC infection. Instead, it is a primary disease of uncontrolled complement activation. In the majority of cases, aHUS is caused by inherited genetic mutations in complement regulatory proteins (e.g., factor H, factor I, MCP) or in activating proteins (e.g., factor B, C3). These mutations lead to a state of chronic, unchecked activation of the alternative complement pathway, resulting in persistent attack on the endothelium. typical vs atypical hemolytic uremic syndrome

Atypical HUS accounts for approximately 10% of all HUS cases. It can affect individuals of any age and often has a more severe and recurrent course than tHUS. Unlike typical HUS